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Tien-Hsien Liquid (THL) is a Chinese herbal mixture that has been used worldwide as complementary treatment for cancer
patients in the past decade. Recently, THL has been shown to induce apoptosis in various types of solid tumor cells in vitro.
However, the underlying molecular mechanisms have not yet been well elucidated. In this study, we explored the eﬀects of THL on
acute promyelocytic leukemia (APL)NB4 cells, which could be eﬀectively treated by some traditional Chinese remedies containing
arsenic trioxide. The results showed THL could induce G2/M arrest and apoptosis in NB4 cells. Accordingly, the decrease of cyclin
AandB1wereobservedinTHL-treatedcells.TheTHL-inducedapoptosiswasaccompaniedwithcaspase-3activationanddecrease
ofPML-RARαfusionprotein.Moreover,DNAmethyltransferase1andoncogenicsignalingpathwayssuchasAkt/mTOR,Stat3and
ERK were also down-regulated by THL. By using ethyl acetate extraction and silica gel chromatography, an active fraction of THL
namedasEAS5wasisolated.Atabout0.5–1%ofthedoseofTHL,EAS5appearedtohavemostofTHL-inducedmultiplemolecular
targeting eﬀects in NB4 cells. Based on the ﬁndings of these multi-targeting eﬀects, THL might be regarding as a complementary
and alternative therapeutic agent for refractory APL.
1.Introduction
Duetotheseveresideeﬀectsandlimitsoftherapeuticeﬃcacy
of conventional cancer treatment, the use of complementary
and alternative medicine (CAM) for improving clinical
outcome and reducing side eﬀects is prevalent worldwide.
Among the various CAM treatment modalities, traditional
Chinesemedicine(TCM)withanticanceractivityisthemost
popular choice. The Tien-Hsien Liquid (THL) is a Chinese
herbal mixture, which has been used as a complementary
anticancer agent for more than 10 years. It mainly consists of
extracts from 14 Chinese medicinal herbs: Cordyceps sinensis
(CS), Oldenlandia diﬀusa (OD), Indigo pulverata levis (IPL;
also known as Indigo naturalis), Polyporus umbellatus (PU),
Radixastragali(RA),Panaxginseng (PG),SolanumnigrumL.
(SNL), Pogostemon cablin (PC), Atractylodis macrocephalae
rhizoma (AMR), Trichosanthes radix (TR), Clematis radix
(CR), Margarite (M), Ligustrum lucidum Ait (LLA) and
Glycyrrhiza radix (GR) [1]. The biological activities of
these herbs have been reported individually, including
antioxidation, antimutagenesis, immunomodulation as well
as cytostatic or cytotoxic eﬀects and so forth. Recently, THL
has been shown to induce apoptosis in many types of cancer
cells and activate caspase-8, -9 and -3 in H1299 lung cancer
cells [2].
Although those studies provided some information
about the molecular basis of THL-induced anticancer activ-
ities, it is worthwhile to investigate additional molecular
mechanisms. One clinically successful example of TCM
therapy is the eﬀective treatment of acute promyelocytic
leukemia (APL) by some traditional Chinese remedies con-
taining arsenic compounds [3, 4]. We attempted to explore2 Evidence-Based Complementary and Alternative Medicine
the eﬀects of THL on the NB4 APL cells and study the related
molecular mechanisms.
Cell-cycle regulation has been suggested as a target for
cancer therapy [5, 6]. Mitotic arrest of cell cycle was an
important mechanism for arsenic trioxide (ATO)-induced
apoptosis in APL cells [7]. There may also be a tight link
between THL-induced apoptosis and arrest of cell cycle.
Therefore, we investigated the inﬂuence of THL on cell-
cycle regulation and the related cyclins and cyclin-dependent
kinase (CDK) in NB4 APL cells.
APL, a particular subtype of acute myeloid leukemia
(AML) with a distinct cytologic morphology (M3 and
M3 variant in French-American-British (FAB) classiﬁca-
tion), is characterized by a chromosome translocation t
(15; 17), which results in the rearrangement of promye-
locytic leukemia (PML) gene and retinoic acid receptor-
α (RARα) gene, and then the expression of PML-RARα
fusion protein [3]. It is commonly accepted that PML-
RARα fusion protein forms the stable complexes with DNA
methyltransferases (DNMTs) and with corepressors, such
as SMRT/NCoR/histone deacetylase, to repress the RARE
(retinoic acid response element)-containing genes [8]. On
the other hand, it is reported that up-regulated DNMTs
may contribute to the pathogenesis of leukemia by inducing
aberrant regional hypermethylation [9]. Eﬀective agents for
APL such as all-trans retinoic acid (ATRA) and ATO are both
able to degrade the PML-RARα [10, 11] and inhibit DNMT
[12, 13]. To more clarify the eﬀects of THL on APL cells, its
inﬂuences on PML-RARα and DNMT1, the most important
DNMT for maintaining the aberrant methylation in cancer
cells [14], were investigated in this study.
Additionally, in leukemia and other hematopoietic dis-
orders, the Akt, Stat and extracellular signal-regulated
kinase (ERK) signaling pathways are frequently activated by
upstreammutationsofcytokinereceptors,aberrantchromo-
somal translocations as well as other genetic problems [15],
resulting in suppression of apoptosis and deregulation of
proliferation [16]. Targeting these oncogenic signaling path-
ways for eﬀective leukemia therapy thus had been proposed
[15]. To understand the eﬀects of THL on APL cells more, its
eﬀects on these signaling molecules were also studied.
In order to improve the potency of THL, we try to
ﬁnd the active components by solvent extraction and silica
gel chromatography. An active fraction named as EAS5 was
isolated, which appears to have much higher potency in
apoptosis induction than THL. The mechanisms underlying
the eﬀects of EAS5 were investigated as well in this study.
2. Methods
2.1. Cell Culture. Human APL NB4 cells were cultured
in RPMI 1640 medium (Gibco, Grand Island, NY, USA)
supplemented with 10% fetal bovine serum (Gibco) and 1%
Penicillin-Streptomycin-Glutamine (100×)l i q u i d( G i b c o ) .
The cells were maintained at 37◦C in a humidiﬁed atmo-
sphere of 95% air and 5% CO2.
2.2. THL and Preparation of Active Fraction EAS5. THL was
provided by Feida Union Pharmaceutical Manufactory, El
Monte, CA. It is an aqueous preparation of herbal mixture
and consists mainly of extracts from 14 Chinese medicinal
herbs as mentioned above. The original THL aqueous
solution was lyophilized, weighed and then stored in −20◦C.
It was reconstituted with sterile distilled water to prepare
the working solutions for experimental use. To isolate the
active fraction EAS5, THL was extracted by ethyl acetate.
Theextractwassubjectedtosilicagelchromatographyeluted
by the gradient ratios of ethyl acetate/n-hexane and then
gradient ratios of methanol/ethyl acetate. The ﬁfth fraction
EAS5 eluted by ethyl acetate/n-hexane (80/20), was found
to be the most potent fraction by its growth-inhibition
activity in various cancer cell lines, including NB4 cells.
Similarly, EAS5 was lyophilized and then weighed to prepare
a5 0m gm L −1 stock solution in dimethyl sulfoxide (DMSO)
and kept in −20◦C. Before being added to cells, the EAS5
stock solution was diluted with PBS to prepare the working
solutions. The ﬁnal DMSO concentrations were all less than
0.1% when EAS5 was added to cells.
2.3. Reagent and Antibodies. The ATRA and antibody against
β-actin (A5441) were purchased from Sigma Chemical Co.
(St. Louis, MO, USA). Primary antibodies against cyclin
A (SC-239), cyclin B1 (SC-245), cyclin D1 (SC-8396),
Cdc2 (sc-54), CDK2 (SC-163), PML (SC-5621), DNMT1
(SC-20701), Stat3 (SC-8019), phosphorylated Stat3 (SC-
7993), ERK (sc-94), phosphorylated ERK (SC-7383) and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (SC-
47724) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Primary antibodies against caspase-
3 (#9661), Akt (#9272), phosphorylated Akt (#9271), mTOR
(#2972) and phosphorylated mTOR (#2971) were purchased
from Cell Signaling Technology (Beverly, MA, USA). Pri-
mary antibody against p21 (05-345) was purchased from
Upstate Biotechnology (Lake Placid, NY, USA). Primary
antibody against RARα (PC92L) was purchased from Cal-
biochem (San Diego, CA, USA).
2.4. Cell Viability Assay. NB4 cells were seeded in 10 cm
dishes at a density of 106 cells/10 cm dish for 24 h and then
treated with drugs or PBS for 3 days. On the day of harvest,
the cell viability was determined by trypan blue exclusion.
2.5. Analysis of Sub-G1 Apoptotic Population and Cell-Cycle
Distribution. One day after being seeded in a six-well
plate (105 cellsmL−1,2 m Lw e l l −1), the NB4 cells were
incubated with THL or EAS5 for the time intervals indicated
in the ﬁgure legends. The control groups were treated
with phosphate-buﬀered saline (PBS) only. At harvest, cells
were ﬁxed in ice-cold 70% ethanol and stored at −20◦C.
Cells were then washed twice with ice-cold PBS and then
incubated with RNase and DNA intercalating dye propidium
iodide (50μgmL −1). The percentages of sub-G1 apoptotic
population and cell-cycle distribution were then analyzed
with a ﬂow cytometer (BD Biosciences, San Jose, CA, USA).
2.6. Western Blot. Western blot was used to examine the
THL-induced changes of caspase-3, cyclins, CDKs, PML-
RARα and DNMT1 proteins, and antibodies against speciﬁcEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Eﬀects of THL on the proliferation of NB4 leukemia
cells. The cells were treated with increasing concentrations of
THL (0.375–3mg/mL) or PBS only for 72h, and cell viability was
determined by trypan blue exclusion. Data (mean ± SE, duplicate)
are expressed as a percentage of the PBS-treated control. SE:
standard error.
phosphorylated proteins were employed to analyze the
activities of aﬀected signaling pathways. Cells were seeded
in 10cm dishes at a density of 106 cells/10cm dish for 24h
and then treated with drugs or PBS for 3 days. On the
day of harvest, the whole-cell lysates were prepared with
radioimmunoprecipitation buﬀer containing 50mM of Tris-
HCl (pH 7.4), 150mM of NaCl, 1% Nonidet-P40, 0.25%
sodium deoxycholate, 1mM of ethylenediaminetetraacetic
acid (EDTA), 1mM of Na3VO4,1 m Mo fN a F ,1 m Mo f
phenylmethanesulfonyl ﬂuoride and 1:100 diluted protease
inhibitors mixture (Sigma). The protein extracts were sub-
jected to sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and transferred to polyvinylidene
diﬂuoride membrane (Bio-Rad, Richmond, CA, USA) by
electroblotting. The membranes were blocked with 5% BSA
in TBST (25mM Tris-HCl, 125mM NaCl, 0.1% Tween
2 0 )f o r1ha tr o o mt e m p e r a t u r ea n dp r o b e dw i t hp r i m a r y
antibody overnight at 4◦C and then with horseradish
peroxidase–conjugated secondary antibody for 1 h at room
temperature. The immune complexes were visualized using
the luminol reagent (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) according to the manufacturer’s instructions.
3. Results
3.1. THL Induced Apoptosis of NB4 Cells. THL dose-
dependently decreased the viability of NB4 cells (Figure 1).
When treated with 0.375mgmL−1 of THL for 72h, only
51.49% of NB4 leukemia cells survived, as compared with
control. At the dose of 1.5mgmL−1, only 6.71% of cells
survived, the IC50 was ∼0.353mgmL−1.
By ﬂow cytometry analysis, a substantial amount of
apoptotic cells with subG1 DNA content could be observed
inTHL-treatedcells.AsshowninFigure 2(a),THLmark edly
increased the percentage of apoptotic population in a dose-
dependent manner. After 3 days of treatment, a total of
Table 1: The THL-induced G2/M arrest in NB4 cells.
Treatment Cell-cycle distribution
Gl (%) S (%) G2/M (%)
PBS 24 h 48.36 32.43 19.21
PBS 48 h 48.01 28.72 23.27
THL1.5mg/mL 24 h 11.45 38.27 50.28
THL 1.5mg/mL 48 h 29.77 14.31 55.93
ATRA 0.25μM 24 h 53.90 29.27 16.83
ATRA 0.25μM 48 h 60.85 18.21 20.94
The cell-cycle distributions of THL- or ATRA-treated cells in Figure 3 were
listed in the Table. THL induced G2/M arrest of cell cycle, in contrast to
the G1 arrest induced by ATRA. THL, Tien-Hsien Liquid; ATRA, all-trans
retinoic acid.
11.63% of subG1 population could be induced by THL at
dose of 0.375 mgmL−1, compared with the 3.13% of PBS
control group. When the dose of THL was greater than
0.75mgmL−1, more than 60% of subG1 population was
observed.
T h et i m ec o u r s eo fT H L( 1 . 5m gm L −1)-induced apopto-
sis was shown in Figure 2(b). A total of 29.97% and 67.94%
of subG1 population were found in THL (1.5mgmL−1)-
treated NB4 cells after 24 and 72h treatment, respectively.
In accordance with that of previous report [2], the THL-
induced apoptosis in NB4 cells was accompanied with the
activation of caspase-3. The cleaved (activated) caspase-3
was dose-dependently increased by THL after 72h treatment
(Figure 2(c)).
3.2. THL Induced G2/M-Phase Arrest. In addition to subG1
apoptotic population, the increase of G2/M-phase popula-
tion was observed in THL-treated cells. This phenomenon
was diﬀerent from that induced by ATRA, a common
agent for treating APL. As shown in Figure 3 and Table 1,
the pattern of cell-cycle distribution induced by THL was
quite diﬀe r e n tf r o mt h a ti n d u c e db yA T R A .A td o s eo f
1.5mgmL−1, THL increased the percentage of cells in the
G2/M phase in a time-dependent manner. After 24 and 48h
ofTHLtreatment,thepercentageofG2/M-phasepopulation
was markedly increased from 19.21 and 23.27% of PBS
control group up to 50.28 and 55.93%, respectively. In
contrast,ATRAprimarilyincreasedtheG1-phasepopulation
(Table 1). After 24 and 48 h of ATRA treatment, the
percentageofG1-phase population wasincreased from48.36
and 48.01% of PBS control group up to 53.9 and 60.85%,
respectively.
The progression of the cell cycle is mainly controlled by
cyclins and CDKs. The cyclin A, cyclin B1 and Cdc2 (CDK1)
are required to pass through the G2/M phase [17, 18].
Therefore, we examined whether these proteins were aﬀected
by THL. After 72h of THL treatment, the western blot
analysis showed the protein levels of cyclin A and cyclin B1
were markedly and dose-dependently decreased. As shown
in Figure 4(a), the protein levels of cyclin A and cyclin B1
were almost completely diminished by THL at doses of
0.75mgmL−1 and 3mgmL−1, respectively. In contrast, the
changes of Cdc2 (Figure 4(a)) and other cell-cycle regulating4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Eﬀects of THL on the apoptosis induction of NB4 cells. (a) THL induced apoptosis of NB4 cells in a dose-dependent manner after
72h of treatment. (b) The time course of THL (1.5mg/mL)-induced apoptosis of NB4 cells. The apoptotic sub-G1 populations in the ﬂow
cytometric analysis histograms were obtained as measures of apoptosis and the percentages of them were shown below the histograms. (c)
The protein level of cleaved/activated caspase-3 of NB4 cells was increased by THL after 72 h of treatment. The cells were treated with PBS
or THL (0.375–3mg/mL) for 72h and then harvested for ﬂow cytometry (a and b) and western blot (c) analysis.
proteins such as cylin D1 and CDK2 were very little. As
shown in Figure 4(b), THL only slightly reduced the protein
levels of cyclin D1 and CDK2 even up to the dose of
3mgmL −1.TheproposedmechanismofTHLinducedG2/M
arrest in NB4 cells was illustrated in Figure 5.
3.3. THL Down-Regulated PML-RARα Fusion Protein and
DNMT1. After 72h of treatment, THL dose-dependently
decreasedthePML-RARαfusionprotein,whichwasdetected
by antibodies against either RARα or PML (Figure 6(a)).
THL almost completely diminished the PML-RARα fusion
protein at the dose above 0.75mgmL−1. This result coin-
cided with the remarkable apoptosis induction shown in
Figure 2(a). As the PML-RARα would cooperated with
DNMT to exert its oncogenic eﬀects [8, 13], we examined
the DNMT1 of THL-treated NB4 cells as well. After 72h
treatment, the DNMT1 was also markedly down-regulated
by THL at the dose of 0.75mgmL−1 (Figure 6(b)). THLEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: Eﬀects of THL on the cell-cycle distribution of NB4 cells. The cell-cycle distributions were analyzed in the ﬂow cytometric analysis
h i s t o g r a m so fT H L( 1 . 5m g / m L ) -o rA T R A( 0 . 2 5μM)-treated NB4 cells after 24 and 48h of treatment. THL induced G2/M arrest in NB4
cells, in contrast to the ATRA-induced G1 arrest. The percentages of cells in diﬀerent phases of the cell cycle are listed in Table 1.
substantially decreased both the PML-RARα and DNMT1
proteins of NB4 APL cells. The scheme explaining these
eﬀects of THL was illustrated in Figure 7.
3.4. THL Inhibited Oncogenic Signaling Pathways. It is
reported that the proliferation and apoptotic resistance of
leukemia cells was closely related to several oncogenic signal-
ing pathways such as Akt/mTOR, Stat3 and ERK [19–24]. In
addition to the inhibitory eﬀects on the aberrantly expressed
orelevatedproteins,wealsoinvestigatetheinﬂuencesofTHL
onthesesignalingpathwaysofNB4cells.After72htreatment
of NB4 cells with THL, the constitutively phosphorylated
Akt protein was decreased in a dose-dependent manner.
Indeed, THLdecreased not only AKT activity butalsodown-
regulated total AKT protein (Figure 8(a)). Similar results
were also observed in the mTOR (mammalian target of
rapamycin), an important downstream mediator of Akt, and
Stat3. THL dose-dependently decreased both the phospho-
rylated and total proteins of mTOR and Stat3 in NB4 cells
(Figures 8(b) and 8(c)).
As shown in Figure 8(d), after 72 h of THL treat-
ment, dramatic inhibition of ERK phosphorylation could
be seen at dose above 0.375mgmL−1.H o w e v e r ,u n l i k ei t s
eﬀects on other signaling proteins such as Akt, mTOR and
Stat3, the total ERK protein level in NB4 cells was only
slightly decreased even at the highest dose of THL. Figure 9
schematically illustrated the eﬀects of THL on the oncogenic
signaling pathways in NB4 cells.
3.5. Active Fraction EAS5 Exerted Most Molecular Targeting
Eﬀects of THL. By ethyl acetate extraction and subsequent
silica gel chromatography, an active fraction named EAS5
was obtained from THL. At about 0.5–1% of the dose
of THL, the active fraction EAS5 could induce apoptosis
and G2/M arrest in NB4 cells. After 72h of treatment,
massive apoptosis (Figure 10(a)) and the increase of cleaved
caspase-3 (Figure 10(b)) were observed in cells treated with
EAS5, even at the lowest dose (3.75μgmL −1). The cell-cycle
distributions shown in Figure 10(a) were outlined in Table 2.
After 72h treatment, the percentage of G2/M-phase cells
was increased from 14.44% of the PBS control group to
23.07 and 44.14% by EAS5 at doses of 3.75 and 30μgmL −1,
respectively. In accordance with the above results, treatment
with EAS5 also resulted in a conspicuous decrease of cyclin
B1. In addition, a broad-spectrum CDK inhibitor p21 [25]
was also markedly increased by EAS5 (Figure 11). The
increased p21 would also inhibit the G2/M phase transition
by Cdc2 inhibition, which was also illustrated in Figure 5.6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: The eﬀects of THL on the cell-cycle regulating proteins of
NB4 cells. (a) THL-induced down-regulation of cyclin A and cyclin
B1 proteins of NB4 cells in a dose-dependent manner but did not
signiﬁcantly change the Cdc2 (CDK1) level. (b) In contrast to its
eﬀects on cyclin A and B1, THL only slightly decreased the protein
levels of CDK2 and cyclin D1. The cells were treated with PBS or
THL(0.375–3mg/mL)for72handthenharvested.Celllysateswere
then prepared for western blot analysis.
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Figure 5: Proposed mechanisms of THL- and its active fraction
EAS5-induced G2/M arrest in NB4 cells. The arrow indicates
promotion, and the T-shaped bar indicates repression. The data of
THL are presented in Figures 3, 4 and Table 1, and the data of EAS5
are presented in Figure 11 and Table 2.
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Figure 6: The eﬀects of THL on the PML-RARα fusion protein
and DNMT1 of NB4 cells. (a) THL dose-dependently decreased the
protein level of PML-RARα detected by antibodies against either
RARα or PML. (b) The protein level of DNMT1 was also decreased
byTHLinthesamemanner.ThecellsweretreatedwithPBSorTHL
(0.375–3 mg/ml) for 72 h and then harvested. Cell lysates were then
prepared for western blot analysis.
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Figure 7: In NB4 cells, PML-RARα expression leads to aberrant
gene methylation by recruitment of DNMT1 and other chromatin
modiﬁers. Both the PML-RARα and DNMT1 could be repressed
either by THL or its active fraction EAS5, which resulted in
apoptosis ofleukemia cells. Thearrow indicates promotion,andthe
T-shapedbarindicatesrepression.ThedataofTHLarepresentedin
Figure 6, and the data of EAS5 are presented in Figure 12.
Like THL, the EAS5-induced apoptosis of NB4 cells was
also accompanied with the down-regulation of both PML-
RARα and DNMT1 proteins. At the dose of 3.75μgmL −1,
EAS5 not only induced massive apoptosis but also dimin-
ished both PML-RARα and DNMT1 of NB4 cells after
72h treatment (Figure 12). These eﬀects by EAS5 were
schematically illustrated in Figure 7. At the same dose, EAS5
also markedly suppressed the Akt/mTOR and ERK signaling
pathways in NB4 cells. EAS5 intensively decreased both theEvidence-Based Complementary and Alternative Medicine 7
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Figure 8: THL-induced inhibition of oncogenic signaling pathways
in NB4 cells. Western blot analysis for phosphorylated (p-) and
total Akt (a), mTOR (b), Stat3 (c) and ERK (d) proteins of THL-
treated NB4 cells. Phosphorylated Akt, mTOR, Stat3 and ERK were
all signiﬁcantly inhibited by treatment with THL. Total protein
levels of Akt, mTOR and Stat3 were also signiﬁcantly decreased by
THL, while the total ERK protein was only slightly decreased by
the highest dose of THL. The cells were treated with PBS or THL
(0.375–3 mg/ml) for 72 h and then harvested. Cell lysates were then
prepared for western blot analysis.
phosphorylated and total Akt protein levels (Figure 13(a)),
and the phosphorylated mTOR was strongly suppressed
by EAS5 as well (Figure 13(b)). Consistent with the eﬀects
of THL on the ERK of NB4 cells, EAS5 also dramatically
decreased the ERK phosphorylation at the lowest dose of
3.75μgmL −1, however, the total ERK protein level was not
aﬀected even at the highest dose (Figure 13(c)). These eﬀects
ofEAS5ontheoncogenicsignalingpathwayswereillustrated
in Figure 9.
Aberrant activation of cytokine or growth factor receptor
JAK
Raf
P13K
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THL Stat3 ERK mTOR THL, EAS5
Deregulations of apoptosis and proliferation
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Figure 9: Schematic illustration of the inhibitory eﬀects of THL
and its active fraction EAS5 on the oncogenic signaling pathways
in NB4 cells. The arrow indicates promotion, and the T-shaped bar
indicates repression. The dramatic inhibition on ERK pathway is
indicated by a thicker T-shaped bar. The data of THL are presented
in Figure 8, and the data of EAS5 are presented in Figure 13.
Table 2: Eﬀects of EAS5 on the cell-cycle distribution of NB4 cells.
Treatment (μgmL −1) Cell-cycle distribution
Gl (%) S (%) G2/M (%)
PBS 56.93 28.62 14.44
EAS5 3.75 55.58 21.08 23.07
EAS5 7.5 48.76 29.60 21.64
EAS5 15 40.74 17.78 41.75
EAS5 30 41.63 14.22 44.14
The cell-cycle distributions of EAS5-treated NB4 cells in Figure 10(a) were
listed in the Table. Like THL, EAS5 also induced G2/M arrest in NB4 cells.
EAS5, active fraction of THL; THL, Tien-Hsien Liquid.
4. Discussion
In the treatment of APL, the successful use of arsenic
compounds contained in some traditional Chinese remedies
revealed the potential of TCM in cancer therapy [3]. We used
the APL cells as a model to evaluate the anticancer eﬀects
of another Chinese remedy THL, which is a herbal mixture
consisting mainly of extracts from 14 Chinese medicinal
herbs and has been used as an anticancer dietary supplement
for more than 10 years. In this study, we comprehensively
elucidated the molecular anticancer mechanisms of THL
against APL cells in the aspects of apoptosis induction,
cell-cycle regulation, down-regulation of PML-RARα fusion
protein and suppression of oncogenic signaling pathways.
Cell-cycle progression is closely related to the prolifer-
ation of cancer cells and therefore becomes the reasonable
target for cancer therapy [5, 26]. There are several types of8 Evidence-Based Complementary and Alternative Medicine
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Figure 10: EAS5 induced apoptosis and activated caspase-3 in NB4 cells. (a) EAS5-induced apoptosis of NB4 cells in a dose-dependent
manner after 72 h of treatment. The apoptotic sub-G1 populations in the ﬂow cytometric analysis histograms were obtained as measures of
apoptosis and the percentages of them were shown below the histograms. (b) The protein level of cleaved/activated caspase-3 of NB4 cells
was increased by EAS5 after 72 h of treatment. The cells were treated with PBS or EAS5 (3.75–30μg/mL) for 72h and then harvested for ﬂow
cytometry (a) and western blot (b) analysis. EAS5: active fraction of THL.
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Figure 11: Eﬀects of EAS5 on the protein levels of cyclin B1 and
p21 in NB4 cells. EAS5 down-regulated cyclin B1 and elevated p21
protein levels in NB4 cells. The cells were treated with PBS or EAS5
(3.75–30 μg/ml) for 72 h and then harvested. Cell lysates were then
prepared for western blot analysis. EAS5: active fraction of THL.
agents targeting the cell-cycle regulating proteins to arrest
the cell cycle including chemotherapeutics. Chemotherapy
agents such as taxol [27] and etoposide [28] induced G2/M
arrest in cancer cells accompanied with the increase of cyclin
B1. Similarly, ATO increased cyclin B1 in NB4 APL [7]
and MCF-7 breast cancer [29] cells but decreased cyclin
B1 in PCI-1 head and neck cancer cells during G2/M
arrest induction [30]. In THL-induced G2/M arrest of NB4
leukemia cells, the cyclin B1 was also decreased rather than
increased. This phenomenon was frequently observed in
cancer cells treated with natural anticancer products, such as
Huanglian [31], theaﬂavin (black tea polyphenol) [32], and
genistein [33]. As THL is composed of a mixture of Chinese
herbal extracts, it would be expected to decrease cyclin B1
during G2/M arrest induction.
THL decreased not only the cyclin B1 but also the cyclin
A protein level of NB4 cells. This phenomenon was also
03 .75 7.51 53 0 0 EAS5 (μg/mL)
PML-RARα
GAPDH
Immunobloted with
anti-PML antibody
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Figure 12: The eﬀects of EAS5 on the PML-RARα fusion protein
and DNMT1 of NB4 cells. EAS5 dramatically decreased the protein
levels of PML-RARα and DNMT1. The cells were treated with PBS
or EAS5 (3.75–30μg/mL) for 72 h and then harvested. Cell lysates
were then prepared for western blot analysis. EAS5: active fraction
of THL.
seen in the G2/M arrest induced by other herbal extracts or
phytochemicals, such as Physalis angulata extract [18]a n d
carnosic acid, a polyphenol present in Rosmarinus oﬃcinalis
[34]. In THL-treated NB4 cells, the cyclin A was suppressed
by a smaller dose than cyclin B1. This phenomenon was
similar to that induced by carnosic acid in Caco-2 colon
cancer cells [34], which resulted in arresting the cell cycle
prior to prometaphase. Therefore, it is speculated that the
major cell-cycle arrest induced by THL may occur before
prometaphase.
A hallmark of APL is a chromosomal translocation that
results in the formation of PML-RARα fusion protein, which
blocksboththeapoptosisanddiﬀerentiationofAPLcells[8].
According to our ﬁndings, THL induced dramatic apoptosisEvidence-Based Complementary and Alternative Medicine 9
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Figure 13: EAS5-induced inhibition of oncogenic signaling path-
waysinNB4cells.Westernblotanalysisforphosphorylated(p-)and
total Akt (a), phosphorylated mTOR (b), phosphorylated and total
ERK(c)ofEAS5-treatedNB4cells.PhosphorylatedAkt,mTORand
ERK were all dramatically inhibited by treatment with EAS5. Total
protein level of Akt was also dramatically decreased by EAS5, while
the total ERK protein was not changed. The cells were treated with
PBS or EAS5 (3.75–30μg/mL) for 72 h and then harvested. Cell
lysates were then prepared for western blot analysis. EAS5: active
fraction of THL.
and down-regulation of PML-RARα fusion protein in NB4
cells but no diﬀerentiation induction was observed (data
not shown). Nason-Burchenal et al. [35]h a dd e m o n s t r a t e d
that cleavage of PML-RARα mRNA by using a hammerhead
ribozyme could trigger only apoptosis in NB4 APL cells but
was insuﬃcient to induce diﬀerentiation. Therefore, it is
possible that THL may target the PML-RARα mRNA by the
similar manner, which remains to be explored.
Recent research has shown that the oncogenic eﬀects of
PML-RARα fusion protein in leukemia were closely related
to the hypermethylation on the promoters of target genes
by recruiting DNMT [36]. DNMT1, the most important
DNMT for maintaining the aberrant methylation [14], had
beenfoundtobeaberrantlyelevatednotonlyinleukemia[9]
but also in many types of cancer cells [37–42]. THL dramati-
callydecreasedbothPML-RARαfusionprotein and DNMT1
during apoptosis induction. The decrease of DNMT1 may
play an important role in THL-induced apoptosis of NB4
cells as it is reported that depletion of DNMT1 could induce
or promote apoptosis of cancer cells [43, 44]. Inhibition of
DNMT1 had been suggested as one of the targeted therapies
for hematologic malignancies [45]. How to down-regulate
DNMT1 appears as a sound approach for epigenetic cancer
therapies [14, 46–48]. Considering its DNMT1 suppressing
eﬀect, THL might have potential as a candidate agent for
epigenetic cancer therapy.
THL-induced apoptosis of NB4 cells may closely corre-
late with the inhibition of the oncogenic signaling pathways,
such as Akt/mTOR, Stat3, and ERK. In acute leukemia
cells, the Akt signaling is frequently activated and strongly
c o n t r i b u t e st op r o l i f e r a t i o na n ds u r v i v a l[ 21]. Constitu-
tive Stat3 activation has been observed in a number of
hematopoietic malignancies, and the apoptosis resistance
in APL cells was hypothesized to be mediated through
the augmentation of Stat3 signaling by the APL fusion
proteins including the PML-RARα [49]. The ERK signaling
is frequently activated in AML cells and down-regulation of
this aberrantly activated ERK had been shown to result in
signiﬁcant apoptosis of the AML blasts [20]. As targeting
these three signaling pathways for eﬀective leukemia therapy
has been suggested [15], the inhibition of all these three
cascades by THL further reveals its potentiality on APL
therapy. Furthermore, the inhibitory eﬀect of THL on ERK
phosphorylation is notably dramatic. This may be useful for
enhancing the therapeutic eﬃcacy of another APL treating
agent ATO. The ATO-induced apoptosis of acute leukemia
cells is counteracted by the induction of ERK activity [50],
and inhibition of ERK activity could enhance apoptosis in
ATO-treated NB4 cells [51]. Therefore, it is speculated that
combined or sequential use with THL plus ATO may provide
the beneﬁcial for APL treatment.
InadditiontoelucidatethecomprehensiveeﬀectsofTHL
against APL cells, we also puriﬁed the active fraction EAS5
from this herbal mixture. It seems that the active anticancer
components in THL are relative hydrophobic, because the
EAS5 was ethyl acetate soluble and eluted by ethyl acetate/n-
hexane (80/20). This hydrophobic property of EAS5 may
make it easier to be absorbed by GI tract. As the EAS5
w a sa b o u to n eh u n d r e dt i m e sm o r ep o t e n tt h a nT H La n d
exerted most of its multi-targeting eﬀects against NB4 cells,
it may be considered as a candidate for future clinical trial of
complementary APL treatment.
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